Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -40.20% is 52% above its 5-year average of -84.13%, near the high end of its 5-year range (-521.83%–-20.16%).
As of the fiscal period ended Tuesday, June 30, 2026. 12.32% above its 12-month average of -45.85%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -40.20%.
RETURN ON EQUITY (ROE)
-40.20%
RETURN ON EQUITY (ROE) AVG TTM
-45.85%
RETURN ON EQUITY (ROE) AVG 3Y
-149.71%
RETURN ON EQUITY (ROE) AVG 5Y
-84.13%
RETURN ON EQUITY (ROE) AVG 10Y
-69.70%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+12.32%
CURRENT VS 3Y AVG
+73.15%
CURRENT VS 5Y AVG
+52.22%
CURRENT VS 10Y AVG
+42.32%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 741 covered companies
CURRENT VS SECTOR MEDIAN
+4.31%
vs the sector median at left
Mustang Bio, Inc.
Market Cap
$3.49M
Return on Equity (ROE)
-40.20%
TTM Avg
-45.85%
3Y Avg
-149.71%
5Y Avg
-84.13%
Market Cap
$3.46M
Return on Equity (ROE)
-89.85%
TTM Avg
30.83%
3Y Avg
-183.24%
5Y Avg
-146.59%
Market Cap
$3.51M
Return on Equity (ROE)
-591.60%
TTM Avg
-213.16%
3Y Avg
-150.57%
5Y Avg
-4.48%
Market Cap
$3.48M
Return on Equity (ROE)
-282.13%
TTM Avg
-313.25%
3Y Avg
-153.55%
5Y Avg
-153.55%
Market Cap
$3.63M
Return on Equity (ROE)
-383.03%
TTM Avg
-1602.50%
3Y Avg
-1094.59%
5Y Avg
-783.90%
Market Cap
$3.27M
Return on Equity (ROE)
-133.43%
TTM Avg
-203.84%
3Y Avg
-174.81%
5Y Avg
-140.61%
Market Cap
$3.25M
Return on Equity (ROE)
-40.75%
TTM Avg
-35.89%
3Y Avg
-218.64%
5Y Avg
-156.11%
Market Cap
$3.68M
Return on Equity (ROE)
N/A
TTM Avg
5741.84%
3Y Avg
2797.55%
5Y Avg
1847.94%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mustang Bio, Inc. (MBIO) | $3.49M | -40.20% | -45.85% | -149.71% | -84.13% |
| Moolec Science S.A. (MLEC)vs › | $3.46M | -89.85% | 30.83% | -183.24% | -146.59% |
| Nexalin Technology, Inc. (NXL)vs › | $3.51M | -591.60% | -213.16% | -150.57% | -4.48% |
| Eocene Ltd. (EOCN)vs › | $3.64M | N/A | N/A | N/A | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.48M | -282.13% | -313.25% | -153.55% | -153.55% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.63M | -383.03% | -1602.50% | -1094.59% | -783.90% |
| Aethlon Medical, Inc. (AEMD)vs › | $3.27M | -133.43% | -203.84% | -174.81% | -140.61% |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.25M | -40.75% | -35.89% | -218.64% | -156.11% |
| Evogene Ltd. (EVGN)vs › | $3.68M | N/A | 5741.84% | 2797.55% | 1847.94% |
| MBody AI Ltd. (MBAI)vs › | $3.16M | 120.45% | 927.43% | 433.61% | 340.10% |
ROE
-40.2%
ROA
-19.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -40.20% |
| 2026-03-31 | -31.68% |
| 2025-12-31 | -20.16% |
| 2025-09-30 | -23.90% |
| 2025-06-30 | -113.31% |
| 2025-03-31 | -296.87% |
| 2023-06-30 | -521.83% |
| 2023-03-31 | -249.62% |
| 2022-12-31 | -167.54% |
| 2022-09-30 | -121.17% |
| 2022-06-30 | -92.61% |
| 2022-03-31 | -73.16% |
| 2021-12-31 | -59.05% |
| 2021-09-30 | -54.76% |
| 2021-06-30 | -46.57% |
| 2021-03-31 | -47.33% |
| 2020-12-31 | -60.97% |
| 2020-09-30 | -72.78% |
| 2020-06-30 | -74.38% |
| 2020-03-31 | -106.18% |
| 2019-12-31 | -89.81% |
| 2019-09-30 | -67.18% |
| 2019-06-30 | -55.01% |
| 2019-03-31 | -119.37% |
| 2018-12-31 | -84.25% |
| 2018-09-30 | -76.67% |
| 2018-06-30 | -65.72% |
| 2018-03-31 | -61.74% |
| 2017-12-31 | -52.29% |
| 2017-09-30 | -37.54% |
| 2017-06-30 | -28.04% |
| 2017-03-31 | -20.17% |
| 2016-12-31 | -52.13% |
| 2016-09-30 | -145.00% |
